BSEBoard Meeting6d ago · 6 Aug 2026, 03:30 pm
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve 1.Unaudited Financial ....
Aspira Pathlab & Diagnostics Ltd · 540788
✦ AI SummaryResults
Aspira Pathlab & Diagnostics Ltd has scheduled a board meeting on August 12, 2026, to consider and approve unaudited financial results for the first quarter ended June 30, 2026, and to consider a proposal for raising funds through a preferential issue of equity shares or warrants.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Intimation for Approval Of Un-Audited Financial Result (Standalone) For The First Quarter Ended On June 30,2026 And To Transact Other Businesses
Attachments (1)
📄pdf
Download →
05c193a0-6922-4a75-9fc2-7e8c199cce06.pdf
View document text
Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand
Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction
LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209
Date: August 6, 2026
Listing Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001.
Security Code: 540788
Security ID: ASPIRA
Sub: Intimation of the Board Meeting
Ref: Prior Intimation under Regulation 29 of the Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015 as Amended (“SEBI Listing
Regulations”) - Board Meeting to be held on August 12, 2026
Dear Sir/Madam,
This is to inform you that pursuant to regulation 29(1) of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015, Notice is hereby given that the meeting of the Board of Directors of the
Company is scheduled to be held on Wednesday, August 12, 2026 inter alia,
1.To consider and approve the Un-Audited Financial Results (Standalone) of the Company for the first
quarter ended June 30, 2026.
2. To consider, evaluate and if deem fit to approve the proposal for raising of funds by way of issuance of one
or more instruments including equity shares or warrants convertible into equity shares of the Company
through preferential issue, private placements, rights issue or any other methods or combination thereof as
may be permitted with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations,
2018 as amended, subject to requisite approvals including shareholders and statutory approvals.
3. To transact other incidental and ancillary matters as may be decided by the board.
The notice of the said Board Meeting will also be uploaded on the Company’s website
www.aspiradiagnostics.com as per regulation 46(2)(l)(i) of the Listing Regulations.
Kindly take the same on your record.
Thanking You.
Yours faithfully,
For Aspira Pathlab & Diagnostics Limited
Nikunj Mange
Executive Director
DIN: 08489442
INDIA’S FIRST 0227197 5756, 022 2513 9090 www.aspiradiagnostics.com
FULLY INTEGRATED LAB support@aspiradiagnostics.com │info@aspiradiagnostics.com